Welcome to our dedicated page for 4D Molecular Therapeutics SEC filings (Ticker: FDMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
4D Molecular Therapeutics filings document financial results, clinical-development disclosures and governance matters for a Nasdaq-listed biotechnology issuer. Form 8-K reports furnish quarterly and annual results and include pipeline updates for 4D-150, the 4FRONT program in wet AMD, and related PRISM and SPECTRA studies in retinal disease.
The company’s proxy materials cover director elections, auditor ratification and executive-compensation votes. Other filings disclose officer appointments and compensatory arrangements, equity awards, registered common stock, and capital-structure actions involving exchanges of common stock for pre-funded warrants with exercise limitations and beneficial-ownership blockers.
4D Molecular Therapeutics director John F. Milligan received a grant of stock options covering 75,000 shares of common stock. The options have an exercise price of $9.42 per share and were automatically granted under the non-employee director compensation program. One-third vests on June 17, 2027, with the rest vesting in equal monthly installments until fully vested on June 17, 2029, or sooner upon a Change in Control, and they expire on June 16, 2036.
4D Molecular Therapeutics director Glenn Sblendorio received a grant of stock options for 50,000 shares of Common Stock. The options have an exercise price of $9.42 per share and expire on June 16, 2036, and are held directly.
The grant was automatically made under the company’s non-employee director compensation program. One-third of the options vest on June 17, 2027, with the remaining shares vesting in equal monthly installments until full vesting on June 17, 2029, or earlier upon a Change in Control under the 2020 Incentive Award Plan. Following this award, Sblendorio holds options for 50,000 shares from this grant.
4D Molecular Therapeutics director Jacob Chacko received a new stock option grant covering 50,000 shares of common stock. The option has an exercise price of $9.42 per share and expires on June 16, 2036. It was granted automatically under the company’s non-employee director compensation program.
The option vests as to one-third of the shares on June 17, 2027, then in equal monthly installments until fully vested on June 17, 2029, contingent on his continued service. The award will also vest in full upon a Change in Control as defined in the 2020 Incentive Award Plan. Following this grant, he holds options for 50,000 shares directly.
4D Molecular Therapeutics director and officer David Kirn reported an open‑market sale of 1,922 shares of Common Stock at a weighted average price of $10.0197 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on January 9, 2026 and was carried out in multiple trades between $10.00 and $10.055 per share.
Following this sale, Kirn directly holds 1,057,231 shares of the company’s common stock, indicating he retained a substantial position after the transaction.
4D Molecular Therapeutics disclosure: RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and principals Peter Kolchinsky and Rajeev Shah filed an Amendment No. 6 to a Schedule 13G/A reporting aggregate beneficial ownership of 5,105,622 shares each (reported under shared voting/dispositive power) representing 9.99% of common stock as of March 31, 2026.
The filing states the Fund directly holds 5,049,779 shares and holds pre-funded warrants exercisable for up to 8,460,000 shares that include a "Beneficial Ownership Blocker" preventing exercise above specified ownership caps; the 9.99% percentage is calculated using 51,051,487 shares outstanding as of March 16, 2026 plus 55,843 shares issuable upon exercise of the pre-funded warrants.
Biotechnology Value Fund and affiliated reporting persons amended a Schedule 13G/A to report their holdings in 4D Molecular Therapeutics as of March 31, 2026. The filing states the Reporting Persons hold Pre-Funded Warrants exercisable for an aggregate of 8,475,665 Shares, with the Pre-Funded Warrants Blocker limiting aggregate exercises to 2,467,230 Shares.
The filing discloses that BVF beneficially owned 3,907,517 Shares (≈7.3%), BVF2 beneficially owned 1,093,101 Shares (≈2.1%), Trading Fund OS beneficially owned 289,025 Shares (<1%), and that certain affiliated entities and persons may be deemed to beneficially own between 9.3% and 9.99% of outstanding Shares using the filing's denominator.
4D Molecular Therapeutics Inc ownership filing shows State Street Corporation beneficially owns 2,707,875 shares of common stock, representing 5.3% of the class as of 03/31/2026. The filing lists shared voting power of 2,647,452 and shared dispositive power of 2,707,875 held through affiliated investment-adviser entities.
The report identifies SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company as relevant subsidiaries or advisory holders. The form is a Schedule 13G disclosure of beneficial ownership and is signed by an authorized officer on behalf of State Street.
4D Molecular Therapeutics, Inc. files a shelf registration to register up to $400.0 million of securities, which includes $200.0 million of unsold securities previously registered and approximately $200.0 million of additional securities.
The prospectus covers multiple classes — common stock, preferred stock, debt securities, warrants and units — to be sold from time to time under a shelf process. The document is a preliminary prospectus dated May 7, 2026 and states that specific offering terms will be provided in prospectus supplements.